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ABSTRACT
Background: Highly active anti-retroviral therapy (HAART) reduces morbidity and 
mortality in HIV/AIDS infected patients. HAART is used indefinitely and the regimens 
are changed over the course of treatment due to resistance, adverse drug reactions or 
access to drugs. Few studies have been done in resource constrained setting to assess 
these factors that have a bearing on compliance and success of treatment.
Objective: To determine the number of patients who changed HAART regimen 
and reasons for change, their CD4+ cell counts and clinical events in the course of 
HAART.
Design: A prospective, observational study.
Setting: Kisumu District Hospital and Nairobi Rheumatology Clinic.
Subjects: Twenty nine of the 101 patients who were on HAART.
Main Outcome Measures: Resistance to HAART, adverse drug reactions, change of 
drugs (HAART) regimen or failed response to HAART regimen.
Results: One hundred and one (60 males and 41 females) patients were screened and 
initiated on HAART. Twenty nine (12 males and 17 females) were included in the 
study. The mean age was 41.7 years, mean CD4+ cell count prior HAART initiation 
was 140.8 cells/µl. Thirteen patients developed treatment failure on HAART and their 
mean CD4+ cell count at the 12th month when the drug were changed was 96.5 cells/µl. 
Five patients developed neuropathy, one developed lipodystrophy, one ART related 
liver injury, three pancreatitis, four changed due to cost and one due to Steven Johnson 
syndrome. Thirteen patients had resistance to HAART and ten of the 13 had new clinical 
events: - cryptococcous meningitis, pulmonary tuberculosis, cytomegalovirus (CMV), 
herpes zoster virus (HZV), pneumocystis jiroveci pneumonia and chronic diarrhoea. 
Five patients had a documented high HIV-RNA viral load mean of 619,919.5 copies/
ml (5.792 log units) at the time of changing HAART at 12 months. Eight of the 13 did 
not have HIV-RNA viral load due to high cost.
Conclusion: Reasons for Changing HAART included: cost of HAART, Poor tolerability 
Toxicities (neuropathy, and lipodystrophy, anti-retroviral related liver injury (ARLI), 
Steven Johnson Syndrome, pancreatitis) and probable failure of to HAART. CD4+ cell 
count was declining in the HAART resistance group. Failing response to HAART in 
routine clinical practice is recognised. Effort must be made to put in place resistance 
surveillance without HAART, CD4+ cell count, HIV viral load and clinical assessment 
are in patients on parameters to consider when changing treatment. 
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INTRODUCTION
Since the introduction of highly active anti-retroviral 
therapy (HAART) for management of HIV/AIDS a 
decade ago, the morbidity and mortality secondary 
to HIV/AIDS have declined dramatically. Indeed, 
HAART has transformed HIV disease into a chronic 
illness requiring long term medical management and 
close follow up (1).
 Once initiated, patients generally remain on 
HAART medications indefinitely. Since resistance 
to HAART is known to occur, there is a risk of 
transmitting a drug resistant virus variant hence the 
necessity to carry out close monitoring of patients. In 
resource constrained setting with the highest burden 
of HIV/AIDS, little work is done to assess the risk 
of HAART resistance and reasons for change in real 
clinical practice. Patients usually present in late stage 
HIV/AIDS with low CD4+ cell counts, single or 
multiple opportunistic infections, wasting and poor 
Karnofsky performance score (2).
MATERIALS AND METHODS
Three hundred and sixty three patients (222 males and 
141 females) who were HIV positive were screened 
for the study. Two hundred and sixty two (162 males 
and 100 females) patients were excluded (referred 
to Mission Hospitals, Provincial General Hospital 
(PGH) Kisumu, Kenyatta National Hospital (KNH) 
comprehensive care clinic as requested). The patients 
were followed up over one year.
 One hundred and one patients (60 males and 41 
females) who were on HAART and HIV care were 
included and followed up. The ethics and standards 
committee of Kisumu District Hospital approved the 
study. The study was done at a time when the free 
access ART project by the ministry of health had not 
been rolled out to peripheral medical facilities in the 
country. These are patients who were able to afford 
HAART and the clinical care was done by one of the 
medical doctor (authors). Informed signed consent 
was obtained form each patient. 
 They were examined by one of the authors on 
every visit or when the condition worsened or they 
developed a new medical condition. Counselling was 
sustained for all the patients to ensure compliance to 
all drugs and clinic attendance. 
 Under aseptic technique, 10 mls of blood 
was drawn from the cubital fossa and used for 
assessment of the following immunological and 
biochemical parameters every three months:- CD4+ 
cell counts, complete blood count, liver function 
tests, urea, electrolytes, and creatinine.  The patients 
were physically examined for weight loss/gain, 
lipodystrophy, skin rashes, jaundice or any new 
clinical event.  
 These were strict criteria hence left out some 
patients who could afford the immunological and 
biochemical follow up every six months (which is 
considered a poor monitoring technique especially 
for the severely immunosuppressed patients).
 The CD4+ cell count was done using the FACS 
(fluorescent activated cell sorter) flow cytometry 
machine with a sensitivity of 1-2000 cells/µl. Serum 
amylases and lipase was done for those who had 
pancreatitis.
 Complete blood count was analysed using the 
coulter counter machine. 
 Blood sugar was analysed using the glucometer, 
ACCU-chek  GO (Roche diagnostics GmbH, 
D-68298 Mannheim, Germany), biochemical 
tests were done thus (AST and ALT by reverse 
passive heamagglutination test (RPHA), Alkaline 
phosphatase and bilirubin  and urea and electrolytes 
by calorimetric method). The weight (Kg) and height 
(cm) of the patients were also taken.
 Three patients had pancreatitis and their serum 
amylase and lipase levels were assessed.  
 The median follow up time was one and half 
years and the follow up is still on. 
 The HAART combinations used were combivir/ 
efavirenz and EMTRI 30/40 ( fixed dose combination 
of lamivudine, nevirapine and stavudine), or 
efavirenz, videx and zerit.
 All the 101 patients had data for one year (CD4+ 
cell count, complete blood count, clinical data) and 
were thus analysable. 
Intervention: HAART was changed appropriately to 
second line. HAART was either:
(i) appropriately changed to second line where there 
was failed response, lipodystrophy, neuropathy 
or cost implications. 
(ii) stopped in Steven-Johnson syndrome, pancreatitis 
and ARLI; the condition managed conservatively, 
then HAART appropriately changed when the 
patients had improved.
RESULTS
Twenty nine (12 males and 17 females) out of 101 
patients were included in the analysis as patients 
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who had to change treatment.
 The male: female ratio of the patients who 
changed the treatment was 1:1.9. Their mean age 
was 41.7 years. The mean CD4+ cell count prior 
HAART initiation was 140.8 cells/µl (12-433). Nine 
patients developed neuropathy at six and nine months 
respectively. One patient had lipodystrophy at nine 
months.
Year starting HAART No. of patients
         2001 16
         2002 20
         2003 33
         2004 20
         2005 8






Shows adverse conditions, reason for change, number of 
patients and ART regimen used.








Neuropathy 5 EMTRI 30/40
Lipodystrophy 1 EMTRI 40
Cost 4 Combivir/
efavirenz
ARLI 1 EMTRI 40









In most cases, HAART results in a reduction in 
plasma viral load to below the limit of detection. 
Regardless of the decrease in morbidity and mortality 
associated with HAART regimens and the significant 
increase in the life expectancy of treated HIV-infected 
individuals, eventual failure of therapy is common 
and poses challenges for future treatment. 
 Changing HAART regimen is often necessary 
because of both acute and chronic toxicities, 
concomitant  new clinical conditions and development 
of virologic failure (3).
 The five patients who had neuropathy and 
lipodystrophy had appropriate mean CD4+ cell count 
response of 104.6, 185.1, 250.8, 321 and 335 cells/µl at 
zero, three, six, nine and 12 months respectively. The 
drug change was necessitated by the adverse event. 
Pancreatitis and lipodystrophy (loss of subcutaneous 
fat in the face, extremities and buttocks) has been 
associated with stavudine, while Steven Johnson 
syndrome, Nevirapine (1%) and Efavirenz (0.1%) 
and is life threatening (3-5).
 Four patients changed drugs due to cost. They 
were on combivir/efavirenz combination and were 
referred to mission hospitals for change to the generic 
formulations, which are affordable. Their compliance 
or effective response was therefore questionable as 
evidenced by the declining mean CD4+ cell counts 
of 141.1, 372.1, 235.6, 200.7 and 101.4 cells/µl at zero, 
three, six, nine and 12 months respectively. Some 
patients could have missed their doses though they 
consented to compliance with treatment. There is 
no available simple test, for example, urine or saliva 
test to quantify and prove compliance to ARTs. Urine 
test for Lamivudine compliance is still under study 
(12).
 Thirteen patients changed drugs due to declining 
CD4 + cell counts. The CD4+ cells declined from a 
mean of 155.2 cells/µl at initiation (zero month) to 
142.8, 180.4, 131.3 to 96.5 cells/µl at three, six, nine and 
12 months respectively. While CD4+ cell counts should 
ideally be done every three months, most patient 
support centres and HIV care clinics test it every six 
months. This may lead to clinical deterioration before 
the patient is identified early enough. The CD4+ cell 
count decline was evident from the 9th month.
 There were also concomitant new clinical events 
noted: cryptococcous meningitis  2, chronic diarrhoea 
due to cryptosporidium 1, herpes zoster virus 
(HZV) 2, cytomegalovirus (CMV) 1, severe wasting 
syndrome 2, tuberculosis (PTB and extrapulmonary) 
3 and pneumocystis jiroveci pneumonia (PJP) 2. The 
CD4+ cell count decline and new clinical events are 
surrogate markers of resistance to HAART. Due to 
S60 East african MEdical Journal December 2013 (Supplement) 
high cost, it was impossible to do HIV-RNA viral 
load for all the patients.  Only 5/13 did the HIV viral 
load at the time of changing the drugs and the mean 
HIV viral load was 619,919.5 virions/ml (5.7921 log 
units). This demonstrated distinct virological failure. 
Virologic failure is defined as HIV RNA > 400 copies at 
24 weeks of therapy, HIV RNA copies of > 50 copies/
ml at 48 weeks of HAART or repeated detection of 
vireamia after virologic suppression (6).  In Africa, HIV 
resistance testing was reported in just five studies and 
suggested resistance mutations in 71 of 594 patients 
(12%). Most of the resistance mutations were to non 
nucleoside reverse transcriptase inhibitors (NRTIs) 
and was mostly 184V (7).  
 HIV-RNA viral load assessment is rarely done 
due to high cost (except in CDC and AMPATH 
sponsored HIV care health facilities). In patients with 
very low CD4+ cell counts like the ones in this cohort, 
it was not clear whether they had secondary resistance 
once HAART was initiated or they had acquired a 
virus which was already resistant to HAART (primary 
resistance).  While the change of HAART depended 
on declining CD4+ cell counts, a surrogate marker 
of higher HIV viral load, clinical deterioration and 
new clinical events (Tuberculosis, cryptococcous 
meningitis, CMV, and cryptosporidium), it has also 
been observed that there are patients whose CD4+ 
cell counts remain low despite adequate HIV-viral 
suppression. This low CD4+ cell count regeneration 
has been associated with a reduced thymic production 
of the CD4+ cells (11). 
 The failure of HAART most likely arises from a 
combination of viral and host factors that facilitate 
the emergence of HIV variants with resistance to 
multiple anti-retroviral drugs. The emergence of 
drug resistance in patients receiving HAART can be 
primarily attributed to the high spontaneous mutation 
rate and high rate of HIV turnover in HIV-infected 
individuals, selective pressure arising from anti-
retroviral therapy, pharmacokinetic characteristics 
of anti-retroviral  drugs, patient tolerance/adherence 
to anti-retroviral regimens and the existence of viral 
reservoirs (15).  
Factors independently associated with a greater risk 
of HIV resistance mutations include (8):
(i) Young age <45 years,
(ii) CD4+ cell counts, < 200 cells/µl at HAART 
initiation,
(iii) HIV viral load > 100,000 copies/ml at HAART 
initiation 
(iv) HIV exposure route which was unknown or other 
than sexual/intravenous drug users (IVDU) 
routes
(v) A previous AIDS diagnosis 
(vi) An unboosted PI-based regimen and
(vii) Triple nucleoside therapy.
HAART can be feasibly administered in resource-
constrained settings and close monitoring is key 
to success of HAART (7). Most of the patients 
23/29 (79.3%) had been initiated on EMTRI 30/40 
(Nevirapine, Stavudine and Lamivudine fixed dose 
combination). Studies have shown that, in severely 
immunocompromised, anti-retroviral-naïve, HIV–1 
infected patients, treatment with efavirenz based 
regimen compared with a non-boosted PI-based 
regimen resulted in a superior virologic response with 
no difference in immunologic or clinical effectiveness 
(9, 10). Adherence and compliance to HAART is 
key to reducing resistance and treatment/segmen 
success. 
 In this cohort, patients presented late with low 
mean CD4+ cell counts of 140.8 cells/µl , young 
age <45 years and this could predispose to ART 
resistance. There were signs of resistance very early 
in the course of treatment at nine months evidenced 
by declining CD4+ cell counts. This could be due to 
their late presentation when they are very sick or 
they may have acquired a mutant HIV-strain with 
primary resistance. 
 Patient adherence is a highly important factor 
in the effectiveness of anti-retroviral regimens. 
Adherence to treatment could be monitored by 
estimation of ART drugs in biological fluids. Indeed, 
a study confirmed the sensitivity and usefulness of 
monitoring urine lamivudine levels in spot specimens 
to monitor patient adherence (12). This will otherwise 
await large clinical trials to confirm it’s sensitivity.
Currently available approaches to measure adherence 
include:
(i) patients’ self-report
(ii) Physician assessments 
(iii) electronic monitoring 
(iv) pill count and 
(v) prescription refill compliance (13). 
Though these methods have proved useful with 
predictive outcomes, the results are variable (13, 14). 
HIV resistance surveillance in resource-constrained 
setting is key before it gets overwhelming. Questions 
arising from this scenario are: (i) do patients with 
very low CD4+ cell counts require HAART resistance 
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testing prior HAART initiation (per patient/
community survey in HIV endemic areas) since 
they will soon switch drugs? and (ii) do the resource 
constrained settings require more potent drugs 
compared to what is in use currently to salvage the 
very sick patients?  
What this paper adds
(i) It documents HAART faiure in routine clinical 
practice in Kenya.
(ii) It emphasises the need to have HIV resistance 
surveillance in resource constrained setting 
before it gets overwhelming.
(iii) In this cohort, patients developed HAART failure 
very early at nine months.
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